Developed by scientists at the VIB University of Ghent, Belgium, the Glyco Liver Profile test from Helena Biosciences is the first of its kind delivering a comprehensive picture of chronic liver disease enabling clinicians to diagnose and monitor patients with hepatic inflammation, fibrosis and cirrhosis while providing a prognostic marker of hepatocellular carcinoma (HCC) risk.
The test is conducted utilising capillary electrophoresis on Helena Biosciences’ V8 NEXUS analyser, with patient results displayed on Platinum 5 Touchscreen software. Dr Adam Stephenson, Director of Sales and Marketing at Helena Biosciences, said: “This is a huge year for the Glyco Liver Profile test and for Helena Biosciences. We have a brand new multi-analyte liver marker that has the potential to be a reference test in hospitals around the world.
“This is a truly innovative test utilising glycomic biomarkers to diagnose and predict the stage and prognosis of liver damage, regardless of the aetiology. Given that we have a global installation base known for myeloma and thalassemia testing, this is one more powerful biomarker that we can roll out to the fleet.”
